Business Wire

VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology ...

AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) ...
EurekAlert!

Leading ALS researchers and clinicians to gather in Chicago for Les Turner Symposium on ALS

CHICAGO – The 2024 Les Turner Symposium on ALS will be held on Monday, Nov. 4 in Chicago. Hosted by the Les Turner ALS Foundation and the Les Turner ALS Center at Northwestern Medicine, this event ...